Researchers reported a dual-target strategy using allogeneic CD19 CAR T cells augmented with an anti-rejection CD70 CAR to address both antigen escape and alloimmune rejection barriers. The approach targets two failure modes that have constrained broader CAR-T deployment, combining recognition of the cancer antigen with engineered mechanisms to improve persistence and reduce immune-mediated rejection. The work is positioned as a potential blueprint for next-generation off-the-shelf CAR T designs where durability and tolerability are central hurdles.